Cardiac Cell-State Transitions During Remodeling: Mechanisms, Clinical Significance, and Therapeutic Implications

Abstract

Cardiac remodeling is a complex biological process involving dynamic shifts in cardiac cell states in response to injury, stress, or hemodynamic overload. These transitions underpin structural and functional changes in the myocardium, influencing disease progression and outcomes in heart failure and other cardiac pathologies. Recent advances in single-cell technologies and lineage tracing have elucidated the heterogeneity and plasticity of cardiac cells, providing new mechanistic insights and identifying potential therapeutic targets. This review synthesizes current evidence on cardiac cell-state transitions, their clinical relevance, and implications for diagnosis and management, with a focus on emerging therapies and guideline-based recommendations for practice.

Introduction

Cardiac remodeling refers to the molecular, cellular, and interstitial changes that occur in the myocardium following injury or sustained stress, such as myocardial infarction, hypertension, or valvular heart disease. Central to this process are transitions in the phenotypic states of cardiomyocytes, fibroblasts, endothelial cells, and immune cells. These cell-state transitions orchestrate adaptive or maladaptive responses, ultimately determining cardiac structure, function, and clinical outcomes. With the advent of high-resolution transcriptomic and proteomic profiling, our understanding of the cellular landscape during cardiac remodeling has expanded significantly, highlighting novel pathways and potential targets for intervention.

Epidemiology / Disease Burden

Heart failure and related cardiac remodeling syndromes affect millions worldwide, constituting a major public health burden. Epidemiological studies estimate that over 64 million individuals are living with heart failure globally, with annual incidences rising due to aging populations and improved survival from acute myocardial infarction. Cardiac remodeling is a pivotal process in the transition from compensated cardiac function to decompensated heart failure, and is a predictor of morbidity, mortality, and health care utilization. Understanding the cell-state transitions involved is essential for risk stratification and therapeutic innovation.

Pathophysiology

Cardiac cell-state transitions are initiated by a myriad of stimuli, including ischemia, mechanical stress, neurohormonal activation, and inflammatory mediators. Cardiomyocytes may undergo hypertrophy, dedifferentiation, or apoptosis, while cardiac fibroblasts transition into myofibroblasts, driving extracellular matrix deposition and fibrosis. Endothelial cells can experience endothelial-to-mesenchymal transition (EndoMT), contributing to vascular rarefaction and myocardial stiffening. Recent single-cell RNA sequencing studies have revealed intermediate states and substantial plasticity in these populations, suggesting that targeting specific cell-state transitions could modulate remodeling outcomes.

Risk Factors

Several clinical and molecular risk factors predispose to maladaptive cardiac cell-state transitions. These include established cardiovascular risk factors such as hypertension, diabetes mellitus, dyslipidemia, and genetic predispositions. Chronic inflammation, persistent neurohormonal activation (e.g., renin-angiotensin-aldosterone system, sympathetic nervous system), and repetitive ischemic insults further exacerbate cell plasticity and pathogenic remodeling. Understanding these risk factors facilitates early identification of patients at high risk for adverse remodeling and guides preventative strategies.

Clinical Features

Clinically, cardiac remodeling manifests as progressive ventricular dilation or hypertrophy, altered wall thickness, and changes in chamber geometry. Patients may present with symptoms of heart failure, arrhythmias, or angina. Physical findings often include displaced cardiac apex, S3 gallop, and signs of volume overload. Diagnostic imaging reveals structural abnormalities, while functional impairment is assessed via echocardiography, cardiac MRI, or biomarkers such as B-type natriuretic peptide (BNP). The extent of remodeling correlates with prognosis and guides management decisions.

Diagnosis

Diagnosis of cardiac remodeling and associated cell-state transitions relies on a combination of clinical evaluation, imaging, and molecular assessments. Echocardiography remains the cornerstone for detecting structural changes and functional impairment. Cardiac MRI provides detailed tissue characterization, including fibrosis quantification. Emerging molecular imaging and biomarker assays (e.g., galectin-3, ST2) offer additional insights into active fibrosis and inflammation. Single-cell RNA sequencing and spatial transcriptomics, though currently research tools, promise future clinical application for detailed mapping of cell-state transitions in vivo.

Treatment & Management

The primary goal in managing cardiac remodeling is to halt or reverse maladaptive cell-state transitions and preserve myocardial function. Standard heart failure therapies, including ACE inhibitors, ARBs, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors, modulate neurohormonal pathways implicated in remodeling. Device therapies such as cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillators (ICDs) are indicated in select patients. Non-pharmacological measures, including lifestyle modification and risk factor control, are also integral to management. Optimal therapy selection is guided by the stage and severity of remodeling, as well as patient comorbidities.

Recent Advances / Emerging Therapies

Recent advances in our understanding of cardiac cell-state transitions have spurred the development of novel therapeutics. Anti-fibrotic agents targeting myofibroblast activation (e.g., pirfenidone, galectin-3 inhibitors) are under investigation in clinical trials. Modulators of immune cell polarization, such as anti-IL-1 and anti-IL-6 therapies, show promise in attenuating inflammation-driven remodeling. Gene-editing approaches and exosome-based therapies aim to directly reprogram maladaptive cell states, restoring regenerative capacity to the myocardium. Precision medicine strategies utilizing single-cell profiling may soon enable personalized interventions targeting specific cell-state transitions in individual patients.

Guideline Recommendations

Contemporary guidelines from the American Heart Association (AHA), American College of Cardiology (ACC), and European Society of Cardiology (ESC) emphasize early identification and aggressive management of cardiac remodeling. Guideline-directed medical therapy (GDMT) is recommended for all patients with heart failure and evidence of remodeling, with consideration of device therapy in appropriate cases. Ongoing risk assessment and monitoring for progression or regression of remodeling are advised, utilizing imaging and biomarkers as adjuncts to clinical evaluation. The integration of emerging molecular diagnostics and targeted therapies is anticipated in future guideline updates.

Conclusion

Cardiac cell-state transitions are central to the pathogenesis, progression, and clinical manifestations of cardiac remodeling. Advances in molecular and cellular profiling have expanded our understanding of these dynamic processes, revealing new therapeutic targets and informing risk stratification. Early and comprehensive management based on guideline recommendations remains essential to mitigate adverse remodeling and improve outcomes. Ongoing research into the mechanisms and modulation of cell-state transitions holds promise for developing precision therapies and transforming the care of patients with cardiac remodeling.